The contractor shall conduct a study to characterize the pharmacokinetic profile of a candidate nucleoside reverse transcriptase translocation inhibitor (nrtti) in rhesus macaques.
Ended Awarded Last action
- Contract number
- 75N93018F00014
- Awardee
-
Advanced Bioscience Laboratories, Inc. UEI MK4QC9EKZXG8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $712,677
Award facts
- Opportunity
-
- NIAIDDAIDSNIHAI2015029 Solicitation number
- Comprehensive Resources for HIV Microbicides and Biomedical Prevention Award Notice · Posted Jun 24, 2015
- Contract value 100% obligated
- $712,676.73 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$45,389 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $758,066 |
About this award
This federal contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Advanced Bioscience Laboratories, Inc. (ABL), a contract research and manufacturing organization specializing in gene therapies, vaccines, and immunotherapies. The $712,676.73 cost-plus-fixed-fee delivery order contract requires ABL to conduct a study to characterize the pharmacokinetic profile of a candidate nucleoside reverse transcriptase translocation inhibitor (NRTTI) in rhesus macaques. This contract is part of the HIV Microbicides and Biomedical Prevention 2016-2021 master indefinite-delivery, indefinite-quantity (IDIQ) contract vehicle. No set-aside was used for this award. As a prime contractor, ABL has previously supported preclinical and clinical product development for NIH and HHS, including manufacturing cGMP batches of vaccines, performing characterization and stability studies, and providing quality control and regulatory documentation services.
Quick answers
Who was awarded contract 75N93018F00014?
75N93018F00014 was awarded to Advanced Bioscience Laboratories, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 1, 2018.
How much is contract 75N93018F00014 worth?
The government has obligated $712,677 on 75N93018F00014.
Is contract 75N93018F00014 an order under another contract?
Yes. 75N93018F00014 is a delivery order under HHSN272201600008I, an indefinite delivery contract, on HIV Microbicides and Biomedical Prevention 2016-2021.
Was contract 75N93018F00014 competed?
The extent of competition for 75N93018F00014 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award